In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Our analysis of options history for Amgen (NASDAQ:AMGN ... Volume & Open Interest Development Assessing the volume and open interest is a strategic step in options trading. These metrics shed ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

Looking at options history for Amgen AMGN we detected 14 trades ... In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules - corrected: reference to date of product launch in Europe removed; link to "Important Safety Information" updated Company aims ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...